Predict your next investment

MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Healthcare
themedicusapp.com

See what CB Insights has to offer

Founded Year

2016

Stage

Seed | Alive

About Medicus

Medicus is a technology-driven platform that brings together various stakeholders of the healthcare industry in India namely doctors and pharmaceutical companies for the betterment of patient care.

Medicus Headquarter Location

India

+9122 61636163

Latest Medicus News

Here are 3 reasons why Pro Medicus (ASX:PME) is a great ASX share to own

Sep 13, 2021

Pro Medicus is a strong business for a number of reasons. Tristan Harrison has been a contributor to The Motley Fool since October 2016. He has an advanced diploma from the Association of Accounting Technicians (UK) and is currently studying to be a Chartered Institute Management Accountant. Tristan's goal is to help Australians learn about the great businesses listed on the ASX that will help grow their portfolio, wealth and confidence about investments over the long term. He's a keen tennis fan and can't wait for the next Australian Open to roll around. You can view Tristan's holdings here . Latest posts by Tristan Harrison ( see all ) Image source: Getty Images The Pro Medicus Ltd (ASX: PME) share price has been a strong performer over the last year, rising by 135%. There are a few different reasons why this business could be a good one to hold for the long-term. What is Pro Medicus? If readers haven’t heard of Pro Medicus before, it describes itself as a leading medical imaging IT provider which was founded in 1983. The company provides a full range of radiology IT software and services to hospitals, imaging centres and healthcare groups around the world. The company boasts that it offers one of the most comprehensive end-to-end offerings in radiology. It has offices in Melbourne, Berlin and San Diego. That’s what the company does. These are some important reasons why investors may want to hold Pro Medicus in their portfolio: Strong profit margins Pro Medicus may be one of the most profitable businesses on the ASX when it comes to its profit margins. The healthcare technology business recently reported its FY21 result which showed a sizeable amount of revenue growth at very high profit margins. It generated a total of $67.9 million of revenue – an increase of 19.5% year on year. With that, the business saw underlying profit before tax growth of 41% to $42.6 million. Net profit rose 33.7% to $30.9 million. The net profit can be a key driver of the Pro Medicus share price. Pro Medicus said that it had an earnings before interest and tax (EBIT) margin of 63.2% for the year. The net profit after tax margin works out to be 45.4%. The higher the profit margins, the more of the new revenue that Pro Medicus can turn into net profit. Major partnerships, client wins and business progress Pro Medicus has won announced a number of positive agreements over the last year or so. There have been some large wins in both Europe and the US. For example, it won a 7-year deal with Intermountain Healthcare, the largest health system in Utah, worth $40 million. Another example would be the $31 million, 7-year deal with the University of California (including all five academic campuses). It has signed research collaboration agreements with NYU Langone Health and Mayo Clinic, which Pro Medicus said were two of the most prestigious academic healthcare institutions in North America. Those agreements were signed to provide a framework for collaboration to facilitate development and commercialisation in the field of AI, utilising the Pro Medicus Visage AI Accelerator platform. Balance sheet and dividends At the current Pro Medicus share price, its dividend only amounts to a fully franked dividend yield of 0.25%. However, longer-term shareholders are benefiting from compounding growth of its dividend. It declared a final dividend of 8 cents per share, bringing the total for the year to 15 cents per share. That full year dividend was an increase of 25% compared to FY20. Shareholders are getting growing cash returns each year. Pro Medicus’ balance sheet remains in a position of strength, it remains debt free. Its cash and other financial assets increased by 42.4% to $61.8 million. Management can use this cash for a variety of purposes like paying dividends, investing for organic growth or potentially making acquisitions. Should you invest $1,000 in Pro Medicus right now? Before you consider Pro Medicus, you'll want to hear this. Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Pro Medicus wasn't one of them. The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more. * And right now, Scott thinks there are 5 stocks that are better buys.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Medicus

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Medicus is included in 1 Expert Collection, including Digital Health.

D

Digital Health

10,285 items

Companies using/incorporating digital tech into health, wellness, and life science offerings. Includes cos operating within the hc, consumer health, and life science industries + tech vendors catering to them. Excludes cos exclusively focused on fitness/sports & performance

Medicus Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Medicus Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.